# Replimune Group said it had reached an agreement with the FDA to resubmit its experimental melanoma drug for approval.

*biotech · news · 2026-05-29 · STAT*

## Key points

- WHO experts recommend using an antiviral and two monoclonal antibodies for Bundibugyo Ebola outbreak.
- Replimune Group reached an FDA agreement to resubmit its experimental melanoma drug after two rejections.
- Allogene CEO David Chang is stepping down from his position.
- Jeremy Levin highlights that scientific progress is outpacing the supporting institutions in biotech.

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Hiya. In this week’s episode of “The Readout LOUD,” biotech vet Jeremy Levin talks about how scientific progress is outpacing the institutions that support it. Also, WHO experts are recommending the use of an antiviral and two monoclonal antibodies in the response to the Bundibugyo Ebola outbreak, and Allogene CEO David Chang is stepping down. Advertisement The need-to-know this morning Replimune Group said it had reached an agreement with the FDA to resubmit its experimental melanoma drug for approval, after the therapy was twice rejected by the agency. Albert Bourla loves China

**Companies:** Replimune Group
**Countries:** China

[Read the full story on STAT](https://www.statnews.com/2026/05/29/biotech-news-allogene-ceo-david-chang-steps-down/)

---

Canonical: https://newsio.io/n/6471a4ba-0c15-47b2-8650-ccf7bd95a6ea/replimune-group-said-it-had-reached-an-agreement-with-the-fda-to-resubmit-its-ex
Summarized by Newsio from STAT. https://newsio.io/how-it-works